Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 4 315 JPY -1.57%
Market Cap: 331.2B JPY

EV/EBITDA
Enterprise Value to EBITDA

7.3
Current
6.8
Median
12.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
7.3
=
Enterprise Value
325B JPY
/
EBITDA
44.4B JPY
EBITDA Growth EV/EBITDA to Growth
JP
Tsumura & Co
TSE:4540
Average EV/EBITDA: 396.2
7.3
26%
0.3
US
Eli Lilly and Co
NYSE:LLY
42.9
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.3
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
8%
1.4
US
Merck & Co Inc
NYSE:MRK
9
9%
1
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
6.3
2-Years Forward
EV/EBITDA
5.7
3-Years Forward
EV/EBITDA
5.3